On February 12th this year, biotechnology company Cleveland Diagnostics, Inc. entered into partnership with Quest Diagnostics– a leading diagnostic information service company across Northern America— to expand the current available methods for prostate cancer detection via novel prostate cancer test, IsopSA.
The collaboration utilized IsoPSA which facilitates a noninvasive, blood-based test. The diagnostic tool demonstrated more rapid and efficient accuracy in terms of prostate-specific cancer cells, as compared to commercially available antigen in the market used as standard care for prostate cancer detection.
IsopSA is designed to be used in triaging patients at risk for high-grade prostate cancer to biopsy. IsopSA is capable of providing additional insights such as determining whether elevated prostate-specific antigen (PSA) level is due to high-grade cancer or other conditions. Efficacy of IsopSA, has been demonstrated in a large, prospective, multicenter clinical study, where significant improvements in detecting high-grad prostate cancer was achieved. Findings confirmed that IsopSA can reduce unnecessary biopsies by as much as 55%.
Cleveland Diagnostic CEO, Arnon Chait, in a press release said that the test will provide physicians and patient with better and definitive understanding of the likelihood of high-grade cancer in their prostate via the new detection tool.
Kristie Dolan, vice president and general manager of Oncology at Quest Diagnostics, in press release, says, “We believe IsoPSA holds great promise to better inform physicians’ diagnostic and treatment decisions for their patients being evaluated for prostate cancer, and we are pleased to work with Cleveland Diagnostics to expand access to this important new test, ultimately bettering patient outcomes by improving the diagnostic process.”
Prostate cancer continues to be one of the leading causes of cancer and cancer deaths, among men. In a 2019 report from American Cancer Society, cases of prostate cancer has observed 3% increase per year from 2014 to 2019. Current trend is linked to rate of new diagnoses of prostate cancer and the lag behind pre-pandemic levels, in which delays in care become contributory to more advanced prostate cancers in the future.
Nonetheless, patients are expected to access IsopSA via their physicians through Quest Diagnostics in the second quarter of 2023. Test results are usually available within three to five days as tests order through Quest network will be processed in Cleveland Diagnostics laboratory in Cleveland, OH, for the meantime.
Read the full story here.
Cleveland Diagnostics is one of Clinical Org’s 20,000+ members. Our regular newsletter reaches the inboxes of clinical labs across the globe. If there’s something you want that audience to see, like your current promotion on coagulation reagents, you can sponsor the newsletter by joining the organization here.